Nature: Why does COVID-19 pneumonia last longer than typical pneumonia and cause more damage?

According to a new study published by Nature, neo-crown pneumonia is significantly different from pneumonia caused by other causes.
shows how the virus hijacks the lungs' own immune cells and uses them to spread through the lungs for weeks.
can cause damage and exacerbate fever, low blood pressure and damage to the kidneys, brain, heart and other organs in patients with COVID-19.
these, scientists have found a target for treating new coronary pneumonia.
viruses that cause pneumonia, such as influenza, can spread over large areas of the lungs within hours.
in modern intensive care units, these bacteria or viruses are usually controlled by antibiotics or the body's immune system in the first few days of illness.
study, published January 11 in the journal Nature, researchers at Northwestern Medicine say COVID-19 pneumonia is different.
SARS-CoV-2 does not infect large areas of the lungs quickly, but instead take root in multiple small areas of the lungs.
then hijacks the lungs' own immune cells and uses them to spread through the lungs for days or even weeks, like multiple wildfires that spread through the forest.
as the infection moves slowly through the lungs, it can leave damage and continue to contribute to fever, low blood pressure and damage to the kidneys, brain, heart and other organs of COVID-19 patients.
coVID-19 may be associated with longer courses than other pneumoniaes, rather than more serious diseases, according to the study's authors.
this is the first time scientists have systematically analyzed immune cells in the lungs of patients with COVID-19 pneumonia and compared them with cells from pneumonia patients with other viruses or bacteria.
detailed analysis, the researchers identified key targets for treating and reducing the risk of severe SARS-CoV-2 pneumonia.
targeting immune cells: macrophages and T-cells.
the study, macrophages, which are usually responsible for protecting the lungs, can be infected with SARS-CoV-2 and help spread the infection through the lungs.
At trachea intestion, the vesicle cavity in patients with severe SARS-CoV-2 pneumonia is rich in T-cells and monocytes, and the vesicle macrophages Northwestern Medicine, which contain SARS-CoV-2rna and expression interferon response genes, will test an experimental drug for these goals in a clinical trial in early 2021 for patients with COVID-19 pneumonia.
tested drugs can suppress the inflammatory response of these immune cells, initiating the repair process of damaged lungs.
, co-author Dr. Ben Singer, an assistant professor of lung and critical care medicine at Feinberg University and a doctor at Northwestern Medicine, said that, like influenza, COVID-19 is unlikely to disappear forever, even if the majority of the population is vaccinated.
"Researchers at Northwestern Medicine and elsewhere are already predicting that this rapidly mutating RNA virus will evade the mechanisms of existing vaccines," Dr. Singer said.
study will help us develop treatments that reduce the severity of COVID-19 patients.
the study also revealed why patients treated with a ventilator for COVID-19 had a lower mortality rate from conventional pneumonia than those who used a ventilator.
risk of death from severe burning of the lungs (common pneumonia).
with COVID-19 pneumonia for a long time, but lung inflammation is not as severe as common pneumonia.
if COVID-19 patients are carefully managed and the health care system is not overwhelmed, health care providers can help them through this period," he said.
although these patients are very ill.
it takes them a long time to get better.
but if you have enough beds and health care, you can keep the mortality rate at 20%.
when health systems are overwhelmed, the mortality rate doubles to 40 per cent.
", so the key point is medical resources.
the study, scientists analyzed the lung fluids of 86 patients with COVID-19 who used a ventilator and compared it with 256 patients with other types of pneumonia who used ventilators.
only a few organizations in the world have analyzed the immune response of the lungs of COVID-19 patients for safety reasons.
, important information about what causes deaths in patients with COVID-19 is lost.
by North western Medicine is unique because the researchers had been studying pneumonia for years before the pandemic.
, when the COVID-19 pandemic hit, they prepared to collect fluid from the lungs of these patients in a safe and systematic manner and compare it with fluid collected in other intensive care unit pneumonia patients before the pandemic.
this research infrastructure allows them to demonstrate that pneumonia in COVID-19 patients is different from other pneumoniaes and, more importantly, how different it is.
scientists extracted cells from the patient's lung fluid and looked at the RNA and proteins they expressed, allowing them to determine how these immune cells cause inflammation.
In summary, the data set provided by this study supports a testable model in which alploic macrophages carrying SARS-CoV-2 form a positive feedback loop with T-cells that secrete IFN-19, promoting albbitis in severe COVID-19 patients.
: Rogan A. Grant, Luisa Morales-Nebreda, Nikolay S. Markov, Suchitra Swaminathan, Melissa Querrey, Estefany R. Guzman, Darryl A. Abbott, Helen K. Donnelly, Alvaro Donayre, Isaac A. Goldberg, Zasu M. Klug, Nicole Borkowski, Ziyan Lu, Hermon Kihshen, Yuliya Politanska, Lango Sichizya, Mengjia Kang, Ali Shilatifard, Christine Qi, Jon W. Kruser, Elizabeth S. Malsin, Chiagozie O. Pickens, Sean B. Smith, James M. Walter, Anna E. Pawlowski, Daniel Schneider, Prasanth Nannapaneni, Hiam Abdala-Valencia, Ankit Bharat, Cara J. Gottardi, G. R. Scott Budinger, Alexander V. Misharin, Benjamin D. Singer, Richard G. Wunderink and The NU SCRIPT Study Investigators. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature, 2021; DOI: 10.1038/s41586-020-03148-wMedSci Original Source: MedSci Original Copyright Notice: All notes on this website "Source: Met Medical Or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medicine, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine."
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here